Needham, MA (PRWEB) March 07, 2013
Metanomics Health GmbH – a BASF Group Company and the Drug Safety Executive Council™ (DSEC™) will expand the evaluation of MetaMap®Tox – a new toxicological profiling tool for biopharmaceutical safety research. Metanomics Health is a BASF Group company and a leader in metabolite profiling. DSEC is an industry consortium focused on supporting the faster development of safer medicines, managed by Cambridge Healthtech Associates™ (CHA™).
Under the new agreement, MetaMap®Tox will be tested for its ability to provide early, reliable detection of cardiotoxicity, one of the major concerns in pharmaceutical drug development. In collaboration with several undisclosed global pharmaceutical partners, MetaMap®Tox will undergo an expanded validation phase, including blinded testing.
“Cardiovascular toxicity is a leading contributor to drug withdrawal and late-stage attrition. There is an urgent need for early detection of cardiotoxicity in pharmaceutical drug development,” said Dr. Ernie Bush, Scientific Director of the Technology Evaluation Consortium™ (TEC) collaborative projects for DSEC. “This project will help our pharmaceutical partners make important progress in their ability to more efficiently evaluate new chemical entities.”
MetaMap®Tox enables an early safety assessment of novel drug candidates by evaluating specific metabolomic patterns in vivo, leading to a better and earlier identification of potential safety risks of novel active pharmaceutical ingredients, an improved understanding of the underlying toxicity mechanisms of action and the ability to translate the findings into clinical practice.
In 2011, MetaMap®Tox obtained technical validation by the DSEC Technology Evaluation Consortium following comprehensive evaluation via this collaborative effort among twelve leading biopharmaceutical companies. It was successfully launched as a service to healthcare clients in June 2012. MetaMap®Tox has been developed in-house by BASF’s Experimental Toxicology and Ecology unit. Before the market launch, it was in routine use at BASF for more than five years. MetaMap®Tox is marketed through Metanomics Health.
“The commercial launch of MetaMap®Tox last year sparked a lot of interest from customers in the healthcare sector,” said Dr. Tim Boelke, Managing Director of Metanomics Health. “Having signed the first agreements on MetaMap®Tox with commercial clients, we believe it is the right time to expand the scope of the solution to advanced cardiotoxicity testing.”
The Drug Safety Executive Council evaluates a number of safety-related new technologies every year through the Technology Evaluation Consortium, which has been serving the industry’s efforts to become more efficient and productive with the development of new biopharmaceuticals for the last 8 years.
“We are proud to be able to bring this evaluation project to our pharmaceutical partners in the industry,” said Dawn Van Dam, General Manager of Cambridge Healthtech Associates and DSEC. “The importance of collaboration in expediting drug discovery cannot be underestimated. We are significantly expanding our efforts in the Technology Evaluation Consortium, and look forward to having many more biopharmaceutical companies and technology providers join our projects to further accelerate the effectiveness and efficiency of the drug discovery process.”
MetaMap®Tox introduction video: http://www.metanomics-health.de/metamaptox-studies-1107.html
Metanomics Health GmbH
10589 Berlin, Germany
Contact for Business Inquiries:
Tel: +49 (0)30-34-807-400
Contact for Media Inquiries:
Tel: +49 (0)30-34-807-402
About Metanomics Health GmbH
Metanomics Health GmbH, a BASF Group company, was founded in 2003 and is a leader in robust, non-targeted and targeted comprehensive metabolite profiling services (metabolomics) to healthcare customers. Serving pharma, nutrition and diagnostics companies, as well as academic partners, the state-of-the-art biomedical data interpretation, combined with innovative bioinformatics and data mining systems, enables discovery and validation of both simple and complex metabolomic biomarkers. Metanomics Health delivers novel biomarkers of disease and drug efficacy, increased mechanistic understanding of drug action and adverse effects, as well as insights into underlying pathways to its partners, thereby providing actionable results for healthcare research and development programs. Learn more at http://www.metanomics-health.de
BASF is the world’s leading chemical company: The Chemical Company. Its portfolio ranges from chemicals, plastics, performance products and crop protection products to oil and gas. We combine economic success, social responsibility and environmental protection. Through science and innovation, we enable our customers in almost all industries to meet the current and future needs of society. Our products and system solutions contribute to conserving resources, ensuring healthy food and nutrition and helping to improve the quality of life. We have summed up this contribution in our corporate purpose: We create chemistry for a sustainable future. BASF posted sales of about €73.5 billion in 2011 and had more than 111,000 employees as of the end of the year. BASF shares are traded on the stock exchanges in Frankfurt (BAS), London (BFA) and Zurich (AN). Further information on BASF is available on the Internet at http://www.basf.com.
Contact for Business Inquiries:
If you are a biopharmaceutical company or technology vendor, and want to join this or other Technology Evaluation Consortium™ projects, please contact:
About Cambridge Healthtech Associates (CHA) and the Drug Safety Executive Council (DSEC)
CHA is the leading organizer of consortia in life sciences. CHA reduces the costs of R&D by bringing companies together to work collaboratively. The Technology Evaluation Consortium determines the scientific utility of new technologies by leveraging the expertise of biopharmaceutical companies. CHA also manages DSEC, an online, peer membership of over 5,000 drug safety leaders. Cambridge Healthtech Associates™ (CHA™) leverages its extensive network and unique collaborative model in consulting, technology evaluations and community-based marketing and communication services to help clients in the life sciences industry commercialize and penetrate the marketplace to increase revenue.